Oligodendroglioma Foundation

28/09/2025

A big step for extending the lives of brain cancer patients took place at The Neuro this week. ❤️

SENTRY™, an innovative technology developed by Montreal-based Reveal and its university partners, was demonstrated for the first time by Dr. Kevin Petrecca, its co-developer. The SENTRY™ can tell cancerous tissue from healthy tissue in real time, allowing surgeons to remove more cancer tissue while keeping healthy tissue intact.

The result of a more than ten-year research collaboration with Frédéric Leblond, a professor at Polytechnique Montréal, this device heralds a new era in AI-assisted precision surgery.

“If we want to prolong patient lives, we have to detect and destroy every cancer cell possible," says Dr. Petrecca. "This technology gives us unprecedented accuracy to find these cells, which significantly increases the chances of surgical success. I am proud to have helped put this powerful new tool into the hands of my fellow surgeons around the world for the benefit of people with this difficult-to-treat disease.”

Learn more: https://www.mcgill.ca/neuro/channels/news/transformation-neurosurgery-368012

-----------------------

Une avancée majeure dans l'allongement de la durée de vie des patients atteints d'un cancer du cerveau a eu lieu cette semaine au Neuro. ❤️

SENTRY™, une innovation développée par la société québécoise Reveal et des partenaires universitaires, permet de distinguer en temps réel les tissus cancéreux des tissus sains, offrant un espoir concret aux patients.

Fruit de plus de dix années de recherche du Dr Kevin Petrecca en collaboration avec le Pr Frédéric Leblond de Polytechnique Montréal, elle ouvre la voie à une nouvelle ère de chirurgie de précision assistée par l’IA.

« Prolonger la vie des patients signifie détecter et éliminer toutes les cellules cancéreuses possibles. Cette technologie offre aux chirurgiens une précision inégalée, augmentant significativement les chances de réussite.. Je suis fier d'avoir contribué à mettre ce nouvel outil puissant entre les mains de mes confrères chirurgiens du monde entier au profit des personnes atteintes de cette maladie difficile à traiter ». — le Dr Petrecca

En savoir plus : https://www.mcgill.ca/neuro/fr/channels/news/une-revolution-en-neurochirurgie-368012

21/09/2025

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).

14/07/2025

https://www.facebook.com/share/1E3sBkRWtM/?mibextid=wwXIfr

First Immunotherapy Trial Designed for Oligo

Last November, Oligo Nation announced the launch of the first immunotherapy clinical trial for oligodendroglioma patients. The trial has been developed by the team at the University of Florida with funding provided by Oligo Nation. This trial utilizes two personalized treatment elements based on the patient’s tumor, a vaccine and t-cells. To be a candidate for this trial, the patient should be considering surgery since tumor from the surgery will be used to develop the personalized vaccine. Immunotherapy is where many recent breakthroughs have happened for other cancers, and we hope this will make a difference for oligodendroglioma patients.

For more information on this trial, go to https://bit.ly/OligoAdoptivetrial or contact Phuong Deleyrolle (phuong.deleyrolle@neurosurgery.ufl.edu).

07/04/2025

https://yale.zoom.us/j/94889839093

20/12/2024

Interesting study:

https://www.linkedin.com/posts/drmelvinsanicas_cell-brain-glioblastoma-activity-7275617778772971520-Qa2o?utm_medium=ios_app&utm_source=social_share_send&utm_campaign=copy_link.

Glioblastomas are not the same as oligodendrogliomas, but some of the factors may show overlap.

Virtually every in the human body has an internal clock. These clocks take their cues from a central clock in the . In a normal, biological process…

07/08/2024

FDA approved Vorasidenib!

Treatment improved PFS by 16 months compared with placebo in INDIGO trial

22/05/2024

Webinar: Empowering brain tumour patients.

Thursday 23 May 2024 at 18:00 EST (12:00 CET)

'Empowering Brain Tumor Patients' webinar this Thursday, May 23, 2024 (6pm EST) with Dr. Isabelle Germano, Dr. Kevin Elmore, and Dr. Stanislav Lazarev. This webinar is hosted by the Icahn School of Medicine at Mount Sinai, in collaboration with the National Brain Tumor Society and the Musella Founda...

10/05/2024

Another interesting read by some of the global oligodendroglioma experts:

https://ascopubs.org/doi/pdf/10.1200/EDBK_431450

"Patients in whom a trial with an IDH inhibitor can be considered are those patients in whom a residual tumor is present but without a need for more definitive treatment with radiotherapy and chemotherapy".

01/05/2024

Review: Focus on current and emerging treatment options for glioma: